Deletion of PRMT1 in mice reduced the expression of PD-L1 and PD-L2 in tumors and reduced the therapeutic effect of anti-PD-1 in HCC mice (60). The gene discussed is PDCD1LG2; the disease is hepatocellular carcinoma.